Curis (CRIS) Competitors

SAB Biotherapeutics (NASDAQ:SABS) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Does the MarketBeat Community favor SABS or CRIS?

Curis received 663 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 83.78% of users gave SAB Biotherapeutics an outperform vote while only 67.38% of users gave Curis an outperform vote.

Company	Underperform	Outperform
SAB Biotherapeutics	Outperform Votes 31 83.78%	Underperform Votes 6 16.22%
Curis	Outperform Votes 694 67.38%	Underperform Votes 336 32.62%

Which has more risk & volatility, SABS or CRIS?

SAB Biotherapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.51, indicating that its stock price is 251% more volatile than the S&P 500.

Do analysts rate SABS or CRIS?

SAB Biotherapeutics presently has a consensus target price of $11.40, suggesting a potential upside of 570.59%. Curis has a consensus target price of $21.00, suggesting a potential upside of 895.26%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Curis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to SABS or CRIS?

In the previous week, Curis had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Curis and 3 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.96 beat Curis' score of 0.22 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation & earnings, SABS or CRIS?

SAB Biotherapeutics has higher earnings, but lower revenue than Curis. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$2.24M	7.05	-$42.19M	-$3.68	-0.46
Curis	$10.91M	1.64	-$47.41M	-$7.03	-0.30

Do institutionals & insiders have more ownership in SABS or CRIS?

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is SABS or CRIS more profitable?

Curis has a net margin of -443.35% compared to SAB Biotherapeutics' net margin of -1,450.14%. SAB Biotherapeutics' return on equity of -94.37% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
Curis	-443.35%	-923.37%	-78.35%

Summary

SAB Biotherapeutics beats Curis on 9 of the 17 factors compared between the two stocks.